Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes

Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Xintong, Yang, Dan, Yang, Guimei, Li, Mengnan, Zhang, Jian, Zhang, Jiaxin, Zhang, Yi, Liu, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531956/
https://www.ncbi.nlm.nih.gov/pubmed/36204104
http://dx.doi.org/10.3389/fendo.2022.984198
_version_ 1784802007379345408
author Hou, Xintong
Yang, Dan
Yang, Guimei
Li, Mengnan
Zhang, Jian
Zhang, Jiaxin
Zhang, Yi
Liu, Yunfeng
author_facet Hou, Xintong
Yang, Dan
Yang, Guimei
Li, Mengnan
Zhang, Jian
Zhang, Jiaxin
Zhang, Yi
Liu, Yunfeng
author_sort Hou, Xintong
collection PubMed
description Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, can stimulate glucose-dependent insulin secretion, particularly by binding to VPAC2 receptors. VIP also promotes islet β-cell proliferation through the forkhead box M1 pathway, but the specific molecular mechanism remains to be studied. The clinical application of VIP is limited because of its short half-life and wide distribution in the human body. Based on the binding properties of VIP and VPAC2 receptors, VPAC2-selective agonists have been developed to serve as novel hypoglycemic drugs. This review summarizes the physiological significance of VIP in glucose homeostasis and the potential therapeutic value of VPAC2-selective agonists in type 2 diabetes.
format Online
Article
Text
id pubmed-9531956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95319562022-10-05 Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes Hou, Xintong Yang, Dan Yang, Guimei Li, Mengnan Zhang, Jian Zhang, Jiaxin Zhang, Yi Liu, Yunfeng Front Endocrinol (Lausanne) Endocrinology Owing to the increasing prevalence of type 2 diabetes, the development of novel hypoglycemic drugs has become a research hotspot, with the ultimate goal of developing therapeutic drugs that stimulate glucose-induced insulin secretion without inducing hypoglycemia. Vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, can stimulate glucose-dependent insulin secretion, particularly by binding to VPAC2 receptors. VIP also promotes islet β-cell proliferation through the forkhead box M1 pathway, but the specific molecular mechanism remains to be studied. The clinical application of VIP is limited because of its short half-life and wide distribution in the human body. Based on the binding properties of VIP and VPAC2 receptors, VPAC2-selective agonists have been developed to serve as novel hypoglycemic drugs. This review summarizes the physiological significance of VIP in glucose homeostasis and the potential therapeutic value of VPAC2-selective agonists in type 2 diabetes. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9531956/ /pubmed/36204104 http://dx.doi.org/10.3389/fendo.2022.984198 Text en Copyright © 2022 Hou, Yang, Yang, Li, Zhang, Zhang, Zhang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Hou, Xintong
Yang, Dan
Yang, Guimei
Li, Mengnan
Zhang, Jian
Zhang, Jiaxin
Zhang, Yi
Liu, Yunfeng
Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title_full Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title_fullStr Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title_full_unstemmed Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title_short Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes
title_sort therapeutic potential of vasoactive intestinal peptide and its receptor vpac2 in type 2 diabetes
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531956/
https://www.ncbi.nlm.nih.gov/pubmed/36204104
http://dx.doi.org/10.3389/fendo.2022.984198
work_keys_str_mv AT houxintong therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT yangdan therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT yangguimei therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT limengnan therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT zhangjian therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT zhangjiaxin therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT zhangyi therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes
AT liuyunfeng therapeuticpotentialofvasoactiveintestinalpeptideanditsreceptorvpac2intype2diabetes

Ejemplares similares